Harris et al. [99] compared sputum microbiome and markers of inflammation in CF patients with a G551D CFTR mutation before and after 6 months of IVA treatment and did not observe any significant change in airway microbial communities or measures of airway inflammation in the overall study cohort. This evidence concerns the gene CFTR and cystic fibrosis.